Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults
by Press Release from Outbreak News Today on (#46GXZ)
Novavax, Inc. announced recently of top-line results of its Phase 2 clinical trial of NanoFlua. The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax' Matrix-Ma adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older. Key findings of the Phase ["]
The post Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults appeared first on Outbreak News Today.